0000000000873444

AUTHOR

Mar Riveiro-barciela

showing 3 related works from this author

Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study

2021

BACKGROUND There is an increased risk of atherosclerosis in patients with chronic hepatitis C or human immunodeficiency virus, but there is scarce data on hepatitis B virus infection. The hypothesis of this study is that hepatitis B virus infection increases the risk of carotid plaques and subclinical atherosclerosis in naïve hepatitis B e antigen (HBeAg) negative subjects. AIM To assess the rate of carotid plaques and subclinical atherosclerosis in naïve HBeAg negative subjects in comparison with a cohort of healthy controls. METHODS Prospective case-control collaborative study conducted in two tertiary hospitals. Four hundred and two subjects prospectively recruited at the outpatient clin…

Carotid Artery DiseasesHepatitis B virusmedicine.medical_specialtyIntima-media thicknessCardiovascular risk Carotid plaques Endothelial dysfunction Hepatitis B virus Intima-media thickness Subclinical atherosclerosis Carotid Intima-Media Thickness Hepatitis B e Antigens Humans Prospective Studies Carotid Artery Diseases Hepatitis B Chronicmedicine.disease_causeCarotid Intima-Media ThicknessGastroenterologyHepatitis B ChronicInternal medicinemedicineHumansOutpatient clinicCarotid plaquesSubclinical atherosclerosisEndothelial dysfunctionHepatitis B e AntigensProspective StudiesRisk factorProspective cohort studyHepatitis B virusbusiness.industryGastroenterologyGeneral MedicineOdds ratioHepatitis BCardiovascular riskmedicine.diseaseIntima-media thicknessHBeAgProspective StudybusinessWorld Journal of Gastroenterology
researchProduct

One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease

2021

BACKGROUND Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). AIMS To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these changes with other HBV markers. METHODS A total of 323 consecutive serum samples from 56 CHD patients (detectable HDV-RNA) followed for >3 years were retested for HDV-RNA levels by a sensitive technique using the first WHO international HDV-RNA standard. Quantitative HBsAg, HBV-DNA, and HBV-RNA were also determined. RESULTS Most participants were male, middle-aged, white European, and HBeAg-negative (82%). Almost half had liver cir…

MaleHepatitis B virusHBsAgmedicine.medical_specialtyCirrhosisHepatitis D ChronicvirusesHbv markersDiseaseGastroenterology03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineNatural courseHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesMiddle Agedbiochemical phenomena metabolism and nutritionSerum samplesmedicine.diseaseHepatitis DDNA ViralRNAQuantitative hbsag030211 gastroenterology & hepatologyHepatitis Delta VirusbusinessAlimentary Pharmacology & Therapeutics
researchProduct

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct